# EDGAR Filing Document

**Accession Number:** 0001365731
**File Stem:** 0001193125-25-319552
**Filing Date:** 2025-12
**Character Count:** 8376
**Document Hash:** 97357e6ba2b1e0e126552acb64d06fdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-319552.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001193125-25-319552

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251211

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Roberts David B
- **CENTRAL INDEX KEY:** 0001365731

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33092
- **FILM NUMBER:** 251572815

**MAIL ADDRESS:**
- **STREET 1:** 55 BRADFORD STREET
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02492
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEMAITRE VASCULAR INC
- **CENTRAL INDEX KEY:** 0001158895
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 63 SECOND AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 781-221-2266

**MAIL ADDRESS:**
- **STREET 1:** 63 SECOND AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Roberts David B<br><sub>(Last) (First) (Middle)</sub><br>C/O LEMAITRE VASCULAR, INC.<br>63 SECOND AVENUE<br><sub>(Street)</sub><br>BURLINGTON, MA 01803<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and Director_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEMAITRE VASCULAR INC [ LMAT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-11 |  | M |  | 25<sup>(1)</sup> | A | 0<sup>(1)</sup> | 23116 | D |  |
| Common Stock | 2025-12-11 |  | F |  | 297<sup>(2)</sup> | D | $83.36 | 22819 | D |  |
| Common Stock | 2025-12-12 |  | M |  | 18<sup>(1)</sup> | A | 0<sup>(1)</sup> | 22837 | D |  |
| Common Stock | 2025-12-12 |  | F |  | 302<sup>(3)</sup> | D | $84 | 22535 | D |  |
| Common Stock | 2025-12-12 |  | M |  | 18<sup>(1)</sup> | A | 0<sup>(1)</sup> | 22553 | D |  |
| Common Stock | 2025-12-12 |  | F |  | 302<sup>(4)</sup> | D | $84 | 22251 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Dividend Equivalent Rights | <sup>(5)</sup> | 2025-12-11 |  | M |  |  | 25<sup>(5)</sup> | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 25 | $0 | 0<sup>(6)</sup> | D |  |
| Dividend Equivalent Rights | <sup>(7)</sup> | 2025-12-12 |  | M |  |  | 18<sup>(7)</sup> | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 18 | $0 | 19.9740 | D |  |
| Dividend Equivalent Rights | <sup>(8)</sup> | 2025-12-12 |  | M |  |  | 18<sup>(8)</sup> | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 18 | $0 | 19.2910 | D |  |

---

### Footnotes:

(1) Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

(2) These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/11/2021. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

(3) These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

(4) These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

(5) These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

(6) Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.

(7) These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

(8) These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

**Signature:** /s/ Laurie A. Churchill, Attorney-in-fact  
**Date:** 2025-12-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**